Company Overview and News
KUALA LUMPUR (Sept 26): Based on corporate announcements and news flow today, companies in focus on Thursday (Sept 27) may include: George Kent (Malaysia) Bhd, Axiata Group Bhd, Astro Malaysia Holdings Bhd, Bumi Armada Bhd, United Malacca Bhd, Poh Huat Resources Holdings Bhd, Malaysia Airports Holdings Bhd (MAHB), Apex Equity Holdings Bhd, Poh Kong Holdings Bhd, Hai-O Enterprise Bhd and Eversendai Corp Bhd
5080 BRDBF 5088 6399 5014 7088 2593 5210 3204 7668 6888 MYPRY AXXTF
KUALA LUMPUR (Sept 26): Furniture maker Poh Huat Resources Holdings Bhd recorded a 4.72% decline in net profit for its third financial quarter ended July 31, 2018 (3QFY19) to RM9.2 million from RM9.66 million a year ago, as its Vietnamese operations faced stiffer competition and lower sales.
Poh Huat Resources Holdings Bhd (July 30, RM1.46) Maintain buy with an unchanged target price of RM1.64: Strong demand for Poh Huat Resources Holdings Bhd’s furniture products would be underpinned by: 1) an improvement in consumer sentiment, 2) an increase in demand for furniture coming from countries like the US as economic growth strengthens, and 3) rising number of housing starts. On top of this, Poh Huat refreshes its product range to sustain its strong orders.
Poh Huat Resources Holdings Bhd (-ve) TRADING of the shares in Poh Huat Resources Holdings Bhd (fundamental: 2.8/3, valuation: 1.8/3) triggered our momentum algorithm yesterday for the first time this year.
KUALA LUMPUR (July 23): Interest in shares of export-oriented furniture manufacturers spiked, following news the United States is looking to impose a 10% tariff on more than 5,000 new Chinese imports worth US$200 billion, which includes furniture.
7006 7088 5101 LIIHF 5001
Poh Huat Resources Holdings Bhd (July 18, RM1.30) Maintain buy with a target price (TP) of RM1.64: Poh Huat Resources Holdings Bhd announced that it had entered into a sales and purchase agreement with JSNJ Investment Pty Ltd, Australia, the owner and developer of a 3,212 square meter (sq m) detached warehouse cum office-showroom in Cranbourne West, Victoria, for a total consideration of A$4.95 million (RM14.
KUALA LUMPUR (July 17): Based on corporate announcements and news flow today, companies that may be in focus tomorrow (July 18) may include the following: Advancecon Holdings Bhd, Hiap Teck Venture Bhd, Poh Huat Resources Holdings Bhd, Velesto Energy Bhd, Barakah Offshore Petroleum Bhd, JAKS Resources Bhd, Star Media Group Bhd, Utusan Melayu (Malaysia) Bhd, Kumpulan Perangsang Selangor Bhd, My EG Services Bhd, Malaysia Airports Holdings Bhd and Kumpulan Jetson Bhd.
5843 5754 6084 7251 5072 4723 9083 MYPRY BSMAF 5014 7088 1818
Poh Huat Resources Holdings Bhd (June 27, RM1.30) Maintain buy with a lower target price (TP) of RM1.64: Poh Huat Resources Holdings Bhd registered a slightly lower revenue by 1.3% year-on-year (y-o-y) of RM287.4 million for the first half ended April 30, 2018 (1HFY18), mainly attributable to lower sales from its Vietnamese operations, given the weaker Vietnam dong to the ringgit but partially offset by higher sales from the Malaysian operations due to continued strong demand for the panel-based bedroom sets for the US market and traditional office furniture.
KUALA LUMPUR: Alam Maritim Resources Bhd , Poh Huat Resources Holdings Bhd , Hai-O Enterprise Bhd , HLT Global Bhd and T7 Global Bhd are among the stocks to watch, according to JF Apex Research.
5115 7668 7088
PETALING JAYA: Shares of Poh Huat Resources Holdings Bhd fell to its lowest in two-and-a-half years after reporting disappointing results for its first quarter ended Jan 31, 2018, a day earlier.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...